SCHEMBL8402292

SCHEMBL8402292

Cc1ccccc1Nc1ncc(-c2ccccc2)c2c(N)n[nH]c12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 12/20 0.80
▸ KDR P35968 2/20 0.46
▸ KIT P10721 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ JAK1 P23458 1/20 0.46
▸ TYK2 P29597 1/20 0.46
▸ JAK3 P52333 1/20 0.46
▸ PDE11A Q9HCR9 4/20 0.43
▸ MAP4K4 O95819 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ LTK P29376 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ CSNK1A1 P48729 1/20 0.41
▸ LIMK1 P53667 1/20 0.41
▸ CDK5 Q00535 1/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ TNK2 Q07912 1/20 0.41
▸ AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8402320 0.90 BTK (0.83) BTKKDRKITFLT3JAK1
SCHEMBL8402297 0.90 BTK (0.72) BTKKDRKITFLT3JAK1
SCHEMBL6115834 0.90 BTK (0.74) BTKKDRKITFLT3JAK1
SCHEMBL1163758 0.89 BTK (1.00) BTKKDRKITFLT3PDE11A
SCHEMBL6115528 0.88 BTK (0.72) BTKKDRKITFLT3MAP4K4
SCHEMBL6115714 0.88 BTK (0.68) BTKKDRKITFLT3MAP4K4
SCHEMBL8402304 0.87 BTK (0.74) BTKKDRKITFLT3
SCHEMBL6115784 0.86 BTK (0.81) BTKKDRKITFLT3PDE11A
SCHEMBL8402340 0.85 BTK (0.66) BTKKDRKITFLT3JAK1
SCHEMBL16161460 0.85 BTK (0.66) BTKKDRKITFLT3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2789615-B1 Azaindazoles as Btk kinase modulators and use thereof BRISTOL MYERS SQUIBB CO (US) 2017-05-03 — — EP disclosed
EP-2789615-A1 Azaindazoles as Btk kinase modulators and use thereof Bristol-Myers Squibb Company (US) 2014-10-15 — — EP disclosed
US-8846673-B2 Azaindazoles as kinase inhibitors and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
US-8846673-B2 Azaindazoles as kinase inhibitors and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2012-05-24 — — US disclosed
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2012-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129852-A1 AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF BTK, ABL1, JAK1 BTK 1/4885KDR 476/4885KIT 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback